Clinical Trials Logo
  1. Home
  2. HIV Infections
  3. NCT00806845
  4. Details
NCT00806845 Clinical Trial

Examination of B Cell Responses in Human Blood

HIV Infections Clinical Trial

Official title:
Gewinnung Humaner antikörperproduzierender Zellen Aus Dem Blut

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00806845
Other study ID # RegMedNet-001
Secondary ID
Status Completed
Phase N/A
First received December 10, 2008
Last updated May 12, 2015
Start date July 2008
Est. completion date February 2010

Study information
Verified date May 2015
Source Regenerative Medicine Network
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Observational

Clinical Trial Summary

The aim of this study is the assessment B-cell immune responses in HIV-infected individuals.

Description:

Groups of patients with different immune competencies will be examined. The impact of HIV infection on immune response will be assessed.

Recruitment information / eligibility
Status Completed
Enrollment 50
Est. completion date February 2010
Est. primary completion date December 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- HIV-infected individuals

- controls

Exclusion Criteria:

- none

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Locations
Country Name City State
Germany Universität Leipzig Leipzig Sachsen

Sponsors (2)
Lead Sponsor Collaborator
Regenerative Medicine Network University of Leipzig

Country where clinical trial is conducted

Germany, 

References & Publications (3)

Bussmann BM, Reiche S, Bieniek B, Krznaric I, Ackermann F, Jassoy C. Loss of HIV-specific memory B-cells as a potential mechanism for the dysfunction of the humoral immune response against HIV. Virology. 2010 Feb 5;397(1):7-13. doi: 10.1016/j.virol.2009.1 — View Citation

Kunz K, Reiche S, Dwai Y, Cordes C, Krznaric I, Bussmann BM, Jassoy C. A broad spectrum of functional HIV-specific memory B cells in the blood of infected individuals with high CD4+ T-cell counts. J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):e56-8. doi: — View Citation

Reiche S, Nestler C, Sieg M, Schulz K, Cordes C, Krznaric I, Jassoy C. Hepatitis C virus (HCV)-specific memory B-cell responses in transiently and chronically infected HIV positive individuals. J Clin Virol. 2014 Apr;59(4):218-22. doi: 10.1016/j.jcv.2014. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Antigen specific B-cell responses 18 months No
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2